Lisa Arthur-Banning
Nurse Practitioner · Clemson, SCNPI 1265679526
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 340 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 340 payments — averaging $15.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$898
- Lilly USA, LLC$626
- Novo Nordisk$565
- AstraZeneca$324
- GSK$280
- Otsuka America Pharmaceutical, Inc.$244
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,202100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 83 | $898 |
| Lilly USA, LLC | 41 | $626 |
| Novo Nordisk | 34 | $565 |
| AstraZeneca | 19 | $324 |
| GSK | 17 | $280 |
| Otsuka America Pharmaceutical, Inc. | 12 | $244 |
| Amgen | 15 | $243 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $201 |
| Nestle Healthcare Nutrition Inc. | 15 | $200 |
| Lundbeck LLC | 9 | $181 |
| Sanofi-aventis U.S. LLC | 11 | $165 |
| Daiichi Sankyo Inc. | 6 | $129 |
| Pfizer | 7 | $113 |
| Tris Pharma Inc | 5 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $93 |
| Biohaven Pharmaceuticals, Inc. | 2 | $92 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $81 |
| Axsome Therapeutics, Inc. | 3 | $68 |
| Dexcom, Inc. | 4 | $65 |
| Sunovion Pharmaceuticals Inc. | 4 | $64 |
| Exact Sciences | 4 | $62 |
| Abbott | 3 | $57 |
| Vanda Pharmaceuticals Inc. | 3 | $53 |
| Corcept Therapeutics | 3 | $45 |
| Bayer | 2 | $39 |
| Novartis | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Johnson & Johnson | 2 | $29 |
| Insmed, Inc. | 2 | $28 |
| Tandem Diabetes Care, Inc. | 1 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Antares Pharma, Inc. | 1 | $13 |
| Adlon Therapeutics L.p. | 1 | $13 |
| Eisai Inc. | 1 | $11 |
How this compares
$5,214 in reported general payments places this provider in the 90th percentile of 1,346 nurse practitioner providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 21 | $41,226 |
| OzempicSemaglutide | 28 | $33,791 |
| JardianceEmpagliflozin | 22 | $23,960 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $21,570 |
| Repatha SureclickEvolocumab | 12 | $12,890 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $12,836 |
| XareltoRivaroxaban | 15 | $11,577 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 75 | $1,896 |
| Levothyroxine Sodium | 185 | $1,747 |
| Duloxetine Hcl | 61 | $1,613 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 66 | $1,570 |
| Omeprazole | 120 | $1,282 |
| FenofibrateFenofibrate Nanocrystallized | 23 | $1,142 |
| Rosuvastatin Calcium | 74 | $1,072 |
| Gabapentin | 81 | $954 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $626 | $41,22621 claims |
| Novo NordiskOzempic | $565 | $33,79128 claims |
| GSKTrelegy Ellipta | $280 | $21,57023 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $165 | $12,83615 claims |
| Johnson & JohnsonXarelto | $29 | $11,57715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,346 nurse practitioner providers in South Carolina.
Other nurse practitioner in Clemson
- David WiltGreenville$90K
- Whitney ReedCharleston$54K
- Mary JohnsonCharleston$34K
- Amanda HareCharleston$30K
- Kellie McLainCharleston$28K
- Colleen BoydSummerville$21K
- Mae BurtonGreenville$21K
- Melissa BramanteColumbia$19K
- Gail KirbyGreer$18K
- Alissa StrojnyMyrtle Beach$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.